Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining topical minoxidil with oral spironolactone improved hair loss outcomes in women with female pattern hair loss when compared to minoxidil alone, but benefits plateaued after 6 months.

In this study, mesotherapy containing nutritional supplements was found to increase patient satisfaction and improve the number of hair follicles more effectively than topical minoxidil in treating female pattern hair loss, though both methods showed similar overall efficacy in hair density and hair loss reduction.

This study found no significant difference in hair outcomes between patients using Minoxidil 1 shampoo and a placebo shampoo for alopecia over four months.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

This study found that while MK-0773 significantly increased lean body mass in sarcopenic frail elderly women, it did not significantly improve muscle strength or physical function compared to placebo.

This study observed that while PrEP was effective among transgender women if taken, adherence was low, especially among those at higher risk.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This study developed a framework to handle missing participant data in systematic reviews for continuous outcomes, finding varied impacts on confidence in effect estimates across reviewed cases.

In this pilot study, no significant differences were observed between memantine and placebo groups in young adults with Down syndrome on the primary memory outcomes, but some improvement was noted in a secondary measure.

This study found that betamethasone valerate foam was more effective and well-tolerated than betamethasone dipropionate lotion in treating mild-to-moderate alopecia areata, with higher hair regrowth rates observed.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This study found that daily use of 1% pyrithione zinc shampoo modestly improved hair growth over 26 weeks, although these effects were less than those of 5% minoxidil.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

This literature review reported that scalp hypothermia significantly decreases the occurrence of chemotherapy-induced alopecia, increasing effectiveness by 2.7-fold in controlled clinical trials and 3.9-fold in randomized trials, and highlighted a need for standard guidelines for its use.

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

This review examines the placebo response in conditions such as allergies and weight loss, highlighting its significance in both conventional and alternative medicine randomized trials, without reporting any new results.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

In a double-blind clinical trial, this study found that a gel containing chitosan-coated spironolactone nanoparticles effectively reduced acne lesions over 8 weeks without adverse skin effects, suggesting potential for enhanced acne treatment through targeted skin delivery.

This letter comments on a randomized controlled trial by Shapiro et al that found no significant benefits of platelet-rich plasma compared to placebo for male androgenetic alopecia, highlighting issues with PRP protocol variations.

CTE can distort results in hair growth trials, so exclude it carefully.

In this study, a 6-month randomized controlled trial with postmenopausal women reported that supplementing with soy protein isolate with isoflavones led to significant improvements in skin hydration and reduced wrinkles and facial pigment intensity, but did not affect sebum production.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This abstract does not provide specific results or a conclusion; additional context is needed to interpret the data.